Click here to view the United Healthcare (UHC) Medical Policy Updates » December 2024 United…
United Healthcare March 2018 Medical Policy Updates
Click here to view the United Healthcare Medical Policy Updates »
March 2018 Medical Policy Updates
UPDATED
- Bone or Soft Tissue Healing and Fusion Enhancement
- Collagen Crosslinks and Biochemical Markers of Bone Turnover
- Cytological Examination of Breast Fluids for Cancer Screening
- Manipulation Under Anesthesia
- Platelet Derived Growth Factors for Treatment of
- Proton Beam Radiation
REVISED
- Abnormal Uterine Bleeding and Uterine Fibroids
- Attended Polysomnography for Evaluation of Sleep
- Balloon Sinus Ostial
- Continuous Glucose Monitoring and Insulin Delivery for Managing
- Elbow Replacement Surgery (Arthroplasty
- Electrical and Ultrasound Bone Growth
- Functional Endoscopic Sinus Surgery (FESS)
- Hearing Aids and Devices Including Wearable, Bone-Anchored and Semi-Implantable
- Hip Resurfacing and Replacement Surgery (Arthroplasty
- Hysterectomy for Benign Conditions
- Implantable Beta-Emitting Microspheres for Treatment of Malignant
- Implanted Electrical Stimulator for Spinal Cord
- Molecular Oncology Testing for Cancer Diagnosis, Prognosis, and Treatment
- Obstructive Sleep Apnea Treatment
- Omnibus
- Pneumatic Compression Devices
- Shoulder Replacement Surgery (Arthroplasty
- Surgical Treatment for Spine Pain
- Temporomandibular Joint Disorders Total Knee Replacement Surgery (Arthroplasty)
- Actemra® (Tocilizumab) Injection for Intravenous Infusion – Commercial Medical Benefit Drug Policy
- Bariatric Surgery – Commercial Medical Policy
- Bone or Soft Tissue Healing and Fusion Enhancement Products – Commercial Medical Policy
- Buprenorphine (Probuphine® & Sublocade™) – Commercial Medical Benefit Drug Policy
- Collagen Crosslinks and Biochemical Markers of Bone Turnover – Commercial Medical Policy
- Denosumab (Prolia® & Xgeva®) – Commercial Medical Benefit Drug Policy
- Electrical Stimulation for the Treatment of Pain and Muscle Rehabilitation – Commercial Medical Policy
- Glaucoma Surgical Treatments – Commercial Medical Policy
- Orencia® (Abatacept) Injection for Intravenous Infusion – Commercial Medical Benefit Drug Policy
- Outpatient Cardiac Telemetry – Commercial Medical Policy
- Platelet Derived Growth Factors for Treatment of Wounds – Commercial Medical Policy
- Proton Beam Radiation Therapy – Commercial Medical Policy
- Respiratory Interleukins (Cinqair®, Fasenra®, and Nucala®) – Commercial Medical Benefit Drug Policy
- Sodium Hyaluronate – Commercial Medical Policy
- Surgical and Ablative Procedures for Venous Insufficiency and Varicose Veins – Commercial Medical Policy
- Temporomandibular Joint Disorders – Commercial Medical Policy
- Transcranial Magnetic Stimulation – Commercial Medical Policy
- Whole Exome and Whole Genome Sequencing – Commercial Medical Policy
RETIRED
- None
Medical Benefit Drug Policy Updates
NEW
- Denosumab (Prolia® & Xgeva®)
UPDATED
- Actemra® (Tocilizumab) Injection for Intravenous
- Orencia® (Abatacept) Injection for Intravenous
REVISED
- None
Coverage Determination Guideline (CDG) Updates
UPDATED
- Blepharoplasty, Blepharoptosis and Brow Ptosis Repair
- Breast Reduction Surgery
- Panniculectomy and Body Contouring Procedures Rhinoplasty and Other Nasal Surgeries
REVISED
- Orthognathic (Jaw) Surgery
- Preventive Care Services
- Speech Language Pathology Services
Utilization Review Guideline (URG) Updates
UPDATED
- Immune Globulin Site of Care Review Guidelines for Medical Necessity of Hospital Outpatient Facility Infusion
REVISED
- Chemotherapy Observation or Inpatient Hospitalization
- Inpatient Pediatric Feeding Programs
- Office Based
- Propranolol Treatment for Infantile Hemangiomas: Inpatient
- Specialty Medication Administration – Site of Care Review Guidelines
REVISED
- Hospital Readmissions
Click here to view the United Healthcare Medical Policy Updates »
Policy Alerts monitors Commercial and Medicare medical policies for changes. While Payers typically update medical policies annually, there are many reasons why a Payer might review or update a policy. When reviews occur out of cycle, they may go unnoticed. Policy Alerts keeps you informed of upcoming and unexpected coverage changes affecting your product. Quickly understanding the changes Payers make can help you adjust reimbursement strategies impacting your business.
Policy Alerts continuously monitors Commercial and Medicare Payer coverage information to keep you up-to-date on Payer decisions in real-time. Whenever changes occur, email notifications containing a summary of those changes are delivered to your inbox. Clients can access detailed coverage reports and medical policies on the interactive Dashboard portal. Save time and keep focused on the important Payer medical policy reviews and coverage decisions affecting your product!
Policy Alerts takes a client-focused hands-on approach and works hard to provide our customers with helpful insights and actionable analytics over raw data. We understand what our clients need and we are dedicated to making sure we provide timely, accurate and always up-to-date reports that can be used to implement and support a successful reimbursement strategy.
Health economic and reimbursement information provided by Policy Alerts is gathered from third-party sources and is subject to change without notice as a result of complex and frequently changing laws, regulations, rules and policies. This information is presented for illustrative purposes only and does not constitute reimbursement or legal advice.
Related Posts
